JP2001518304A5 - - Google Patents

Download PDF

Info

Publication number
JP2001518304A5
JP2001518304A5 JP2000513958A JP2000513958A JP2001518304A5 JP 2001518304 A5 JP2001518304 A5 JP 2001518304A5 JP 2000513958 A JP2000513958 A JP 2000513958A JP 2000513958 A JP2000513958 A JP 2000513958A JP 2001518304 A5 JP2001518304 A5 JP 2001518304A5
Authority
JP
Japan
Prior art keywords
seq
multifunctional protein
interferon
group
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000513958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001518304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/020464 external-priority patent/WO1999016889A1/en
Publication of JP2001518304A publication Critical patent/JP2001518304A/ja
Publication of JP2001518304A5 publication Critical patent/JP2001518304A5/ja
Withdrawn legal-status Critical Current

Links

JP2000513958A 1997-10-01 1998-09-30 アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用 Withdrawn JP2001518304A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6060997P 1997-10-01 1997-10-01
US60/060,609 1997-10-01
PCT/US1998/020464 WO1999016889A1 (en) 1997-10-01 1998-09-30 Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment

Publications (2)

Publication Number Publication Date
JP2001518304A JP2001518304A (ja) 2001-10-16
JP2001518304A5 true JP2001518304A5 (https=) 2006-01-05

Family

ID=22030604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000513958A Withdrawn JP2001518304A (ja) 1997-10-01 1998-09-30 アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用

Country Status (5)

Country Link
EP (2) EP1019515A1 (https=)
JP (1) JP2001518304A (https=)
AU (1) AU9673998A (https=)
CA (1) CA2303401A1 (https=)
WO (1) WO1999016889A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2313251A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO1999061464A1 (en) * 1998-05-28 1999-12-02 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2004240199B2 (en) * 1999-04-30 2007-05-17 Novartis Vaccines And Diagnostics S.R.L. Conserved Neisserial antigens
CA2400403C (en) * 2000-02-18 2011-07-19 New York Medical College 1-nitroacridine/tumor inhibitor compositions
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
AU2002239366A1 (en) 2000-11-28 2002-06-11 Geetha Kassam Anti-angiogenic polypeptides
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CN100543036C (zh) * 2002-05-06 2009-09-23 得克萨斯州大学系统董事会 递送治疗或诊断试剂的导向蛋白质
JP4511108B2 (ja) * 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
EP1581164A4 (en) 2002-12-13 2008-03-12 Mediomics Llc COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF TUMORS AND METASTASES
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2628748A1 (en) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin chimeras and uses thereof
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EP2995626B1 (en) * 2013-05-06 2018-07-11 China Pharmaceutical University Bifunctional fusion proteins to inhibit angiogenesis in tumour microenvironment and to activate adaptive immune responses and the genes and uses thereof
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CN114058636A (zh) * 2021-11-16 2022-02-18 大连润生康泰医学检验实验室有限公司 一种转甲状腺素蛋白基因的克隆、表达与纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
AU615919B2 (en) * 1987-07-01 1991-10-17 Beecham Group Plc Hybrid plasminogen activators
ATE240740T1 (de) * 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
NZ307044A (en) * 1995-04-26 2002-03-01 Childrens Medical Center Angiostatin fragments with antiangiogenic activity
US5824299A (en) * 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
JP3840262B2 (ja) * 1995-10-23 2006-11-01 ザ チルドレンズ メディカル センター コーポレイション 治療用の抗血管新生組成物および方法
US5837680A (en) * 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
AU761027B2 (en) * 1998-08-25 2003-05-29 Merck Patent Gmbh Expression and export of angiostatin and endostatin as immunofusis

Similar Documents

Publication Publication Date Title
JP2001518304A5 (https=)
JP2557053B2 (ja) 腫瘍壊死因子の精製、製造および使用法
EP0211148B2 (en) Mature human leukozyte interferons, process for their bacterial production, intermediates therefor and compositions containing them
US4456748A (en) Hybrid human leukocyte interferons
US6187751B1 (en) Biologically active peptide of ob protein
EP0051873A2 (en) Hybrid human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them
JP2002528060A5 (https=)
JP2004531242A5 (https=)
CA2641565A1 (en) Nel-related proteins type 1 and 2, and polynucleotides encoding them
JP2004536077A5 (https=)
KR20000016402A (ko) 렙틴(ob단백질)의 프레그먼트
CA2311648A1 (en) Ifnar2/ifn complex
CN101463089B (zh) 人血清白蛋白-干扰素融合蛋白及其编码基因与应用
Van Poelje et al. Cloning, sequencing, expression, and site-directed mutagenesis of the gene from Clostridium perfringens encoding pyruvoyl-dependent histidine decarboxylase
CA1339464C (en) ¬leu13| motilin, dnas coding for same and methods for producing same
EP0534568B1 (en) Human growth hormone analogues and their use
PT96224A (pt) Producao de factor de crescimento derivado de plaquetas biologicamente activas a partir de sistema de celulas hospedeiras de elevada expressao
JP2004533846A5 (https=)
EP0189784B1 (en) Human natural inhibitor of collagenases
RU2005101076A (ru) Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации
CN101735200B (zh) 喹唑啉类化合物
JP2008502323A5 (https=)
JP2009507474A5 (https=)
CA2465667A1 (en) New peptides - analogs of human growth hormone-releasing hormone
CN102949731A (zh) 与glp-2受体特异性结合的药物融合体